Structured around discovery and development of novel peptides for treatment of metabolic diseases, AmideBio leverages its proprietary BioPureĀ peptide manufacturing technology to supply ultrapure peptides for research purposes. A biotech company having created their BioPure platform technology to manufacture peptides and proteins, the focus is on therapeutic targets and diagnostics invvolving diabetes, and neurodegenerative diseases and has generated a series of different types of insulins to improve stability issues that limit the growth of existing insulin. The BioPure platform supports production of proinsulin, toxins, boowman-birk inhibitors and several other crucial peptides. The company also produces amyloids for Alzheimer's research.
